

# ForPatients

by Roche

Hemophilia A

## A Study of Efficizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN2)

A Study of Efficizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

**Trial Status**  
Completed

**Trial Runs In**  
10 Countries

**Trial Identifier**  
NCT02795767 2016-000073-21,  
HAVEN2 BH29992

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02795767 2016-000073-21, HAVEN2 BH29992**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
<= 17 Years

**Healthy Volunteers**  
No

---